scispace - formally typeset
K

Katri Rosenthal-Aizman

Researcher at Stockholm University

Publications -  8
Citations -  872

Katri Rosenthal-Aizman is an academic researcher from Stockholm University. The author has contributed to research in topics: Membrane & Cyclic peptide. The author has an hindex of 6, co-authored 8 publications receiving 797 citations.

Papers
More filters
Journal ArticleDOI

Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo.

TL;DR: A novel CPP, PepFect 6 (PF6), comprising the previously reported stearyl-TP10 peptide, having pH titratable trifluoromethylquinoline moieties covalently incorporated to facilitate endosomal release is presented, implying that the peptides, in addition to having utility for RNAi screens in vitro, displays therapeutic potential.
Journal ArticleDOI

Cell-penetrating peptides: A comparative membrane toxicity study

TL;DR: In this article, a new class of delivery vectors with high pharmaceutical potential, called cell-penetrating peptides (CPPs), were proposed. But the ability of these peptides to translocate through cell membranes can be limited.
Journal ArticleDOI

Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.

TL;DR: Cell-penetrating peptide conjugation of MTX is a new way of increasing delivery, and thereby, the potency of already well-characterized therapeutic molecules into drug resistant tumour cells.
Journal ArticleDOI

Self-Assembling Peptide Nanotubes from Enantiomeric Pairs of Cyclic Peptides with Alternating d and l Amino Acid Residues

TL;DR: Results strongly indicate the formation of peptide nanotubes that assemble with one enantiomer in every second position, thereby forming a lamellar structure.
Journal ArticleDOI

Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors

TL;DR: In this article, a novel homing peptide that recognizes tumor vessels and invasive tumor satellites in glioblastomas was identified, and the peptide-targeted delivery of chemotherapeutics prolonged the lifespan of mice bearing invasive brain tumors and significantly reduced the number of tumor satellites.